1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Vaccine Sales Analysis 2016-2026: Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases

Vaccine Sales Analysis 2016-2026: Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases

  • March 2016
  • 186 pages
  • ID: 3827256
  • Format: PDF
  • Visiongain


Table of Contents

Report Details
Vaccines – Your 2016 Guide to Developments, Opportunities and Revenues
What does the future hold for vaccine sales? Visiongain’s updated report shows you forecasted sales at overall world market, submarket, product and national level to 2026.

With that study you discover vaccine trends, R&D and revenue prospects for human healthcare. That way you can benefit your research, analysis, decisions and authority. For those technologies, assess sales potentials and opportunities.

Vaccines still hold great technological, medical and commercial potential. See why and what is possible. Read on, then, to explore that industry and see a revenue prediction.

Forecasts from 2016 to 2026 and other analyses showing you vaccine market potentials
Besides revenue forecasting to 2026, our new study gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).

Our report gives you 52 tables and 56 charts. Gain analysis found nowhere else. Discover what the future holds for companies and the vaccines market.

Gains through exploring the vaccines industry – ways to benefit your plans and decisions
Leaders hold the latest knowledge – research and analysis. So explore, in our report, the development, production and sales of vaccines. There, from 2016, you see where needs and money exist for those preventative medicines. Discover what is possible.

Our study’s purpose is to help you avoid struggles to gain business data on vaccines. See how our predictions and discussions could benefit your reputation for commercial insight.

Discover, then, how you and your organisation can gain. The following sections show how our new investigation benefits your plans, decisions and presentations.

Revenues for the world vaccines market and submarkets – what is possible?
What is that industry's potential? What are the secrets of its progress? Discover in our report overall world revenue forecasting to 2026. Also find individual predictions for four world level submarkets:
- Paediatric vaccines
- Adult vaccines
- Elderly vaccines
- Travel vaccines.

How will sales rise? And which product classes can generate most revenue? In our work you assess prospects for commercial expansion. You see which vaccine types hold greatest potential for sales growth and high revenues.

Benefit your knowledge and authority. You also discover sales potentials of vaccines by brand.

Forecasts and discussions for leading marketed products
How will leading brands perform from 2016 at world level? Our work shows you 10 individual revenue forecasts to 2026 for leading vaccines:
- Prevnar
- Gardasil
- Fluzone
- Pentacel
- ProQuad/M-M-R- II/Varivax.

You also see revenue predictions to 2026 for these products:
- Infanrix/Pediarix
- Zostavax
- RotaTeq
- GSK hepatitis franchise
- Menactra.

Avoid falling behind in information to help you stay competitive. Instead our work lets you assess potentials, seeing activities, results and outlooks. You discover what is happening, exploring trends, competition and sales prospects.

Our study also divides its overall world vaccines forecast into geographical regions.

Healthcare in national markets – what outlooks for sales of those medicines?
Progress worldwide in vaccines and healthcare from 2016 will increase vaccination. With our investigation you hear about the best revenue prospects for those medicines, assessing national prospects.

Our analysis shows you individual revenue forecasts to 2026 for 11 national markets:
- United States (US)
- Japan
- Germany, France, United Kingdom, Italy and Spain (EU5 countries)
- Brazil, Russia, India and China (BRIC group).

There you assess developed and developing countries for revenues and future sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Future vaccines – assess emerging technologies, exploring research and development
Our study also shows you the most promising vaccines in development. There explore product candidates in these six classes:
- Prophylactic vaccines
- Products for children
- Agents for protecting adults
- Treatments for older people
- Travel vaccination
- Therapeutic vaccines.

R&D for vaccines holds great potential to benefit companies, healthcare providers and patients. See what technological, clinical and commercial opportunities exist, helping you stay ahead.

Our study explains progress in human prophylaxis, discussing issues to help your work.

Events affecting developers, producers and sellers of vaccines
Assess forces affecting that industry and market from 2016, including these issues:
- Importance of vaccine production to the pharmaceutical industry
- Immunisation needs and progress in developed and developing countries
- Rising vaccination needs in emerging countries and under-developed regions, including fighting influenza pandemics and the Zika virus
- Developments for combating HIV, cancer, addictions and other emerging uses
- Delivery systems and other innovations improving vaccines’ performance.

With our survey you explore political, economic, social and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market, seeing what the future holds.

Leading vaccine producers and that industry’s overall 2020 market value
What happens next? Our report predicts the overall world market for vaccines will reach $49.8bn worldwide in 2020, with strong revenue expansion from 2016 to 2026.

See how high its revenues can go. Discover in our work what is possible for vaccine production and sales, and see which companies hold greatest potential.

In particular our work assesses these organisations:
- GlaxoSmithKline
- Merck & Co.
- Sanofi
- Pfizer
- Johnson & Johnson
- AstraZeneca.

From 2016 to 2026 vaccines will benefit patients, payers and companies, rising in prominence. Our analysis predicts advances there. Stay ahead by getting that study.

Ways Vaccine Sales 2016-2026 benefits your work – gain data you find nowhere else
In particular, our new investigation gives you these analyses to help your research, plans, decisions and proposals:
- Revenues to 2026 for vaccines at world level and for 4 main submarkets – assess prospects for investments, marketing and sales
- Predictions for 10 products to 2026 – discover revenue potentials of leading vaccines, seeing how they can compete and succeed
- Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for potential revenues
- Prospects for established competitors and rising companies – explore products, R&D and outlooks for success.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.

With our study, by visiongain’s UK-based analysts, you avoid missing out on data to help you stay ahead. See what the future holds for vaccine developers, producers and sellers.

Trying our new report now lets you discover vaccine trends, opportunities and forecasts
Our investigation is for everyone analysing preventive medicines and related biotechnology. There you discover data and forecasts for human vaccines. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on